Efficiency01
80 %
Reduced screening effort
A highly selective candidate pool reduces laboratory screening by up to 80%, and the phage display bottleneck is eliminated.
Fully synthetic nano-antibodies · 100% animal-free
We develop fully synthetic nano-antibodies (VHH): without a single laboratory animal, with unmatched precision and in weeks instead of months.
For 500 million years, only vertebrates could produce fully functional antibodies. We have fundamentally changed that.

The problem
Conventional, animal-based methods have become the bottleneck of pharmaceutical research, with four shortcomings that cause massive sunk costs every year.
Current methods rely on animal immunization or animal-derived libraries, using and losing millions of animals per year and raising considerable ethical and regulatory concerns.
Immune tolerance in animal systems prevents robust responses against highly conserved human proteins, including crucial cancer markers. It is precisely the most important targets that remain inaccessible.
Conventional antibody generation typically takes 6 to 12 months, which makes it unsuitable for time-critical scenarios such as pandemics or rapidly progressing diseases.
Animal-based workflows are costly, resource-hungry and uncertain: low screening efficiency and limited reproducibility lead to high development risk.
The technology
Instead of bulky classical IgGs, we develop nano-antibodies: 10x smaller, extremely stable, deeply tissue-penetrating and modular. Our platform combines unlimited synthetic diversity with the functionality of the vertebrate immune system, recreated in bacteria.
Stability, tissue penetration and low immunogenicity for multifunctional applications.
Synthetic libraries bypass immunological blind spots: new specificities become accessible.
Functional selection yields up to 100% functional clones, unmatched by competitors.
Built on standard biotechnology: extreme selection pressures, industrial scale-up.
Synthetic diversity
Fully synthetic, randomized gene libraries generate exceptional diversity: sequence polymorphisms and targeted length variations across the CDR1–CDR3 regions. This massively expands the accessible binding space.
Functional selection
A bacterial recreation of B cell maturation enriches exclusively correctly folded, functional nano-antibodies. Dysfunctional clones (up to 80% in classical libraries) are systematically eliminated early on.
SporoBead display
Selection takes place on bacterial endospores: stable genotype-phenotype coupling even under the harshest washing conditions, giving full access to the diversity without the losses of classical display technologies.
// Animal testing
0%
Laboratory animals: completely animal-free development
// Screening
80%
less screening effort, faster from hit to lead
// Clones
100%
functional clones, the full potential of every library
// Diversity
20000000
* infinite antibody universe: access to novel targets …
Your benefit
The combination of a fully synthetic library, functional selection and SporoBead display delivers technological, economic and regulatory advantages.
Efficiency01
80 %
A highly selective candidate pool reduces laboratory screening by up to 80%, and the phage display bottleneck is eliminated.
Speed02
Fewer iterations, faster from hit to validated lead: weeks instead of months.
Success rate03
Unstable or non-functional variants are eliminated early. What remains, binds.
VHH advantage04
10×
10x smaller than IgGs: higher binding density and extreme thermal and chemical stability.
Reach05
Binders against conserved or structurally challenging epitopes, previously out of reach.
Precision06
Active control of cross-reactivities through combined positive and negative selection.
Robustness07
Fully synthetic and independent of immune responses or secretion systems: reproducible by design.
Quality08
≥99 %
Validated purity ≥ 99%, high yields and immediate scalability.
BESTBODIESApplications · BESTBODIES
From research through in vitro diagnostics to therapy: our nano-antibodies open doors that remain closed to conventional antibodies.
BSR HIA
2026
Winner
of the award
Awarded & validated
We have successfully validated our platform and produced the first high-affinity nano-antibodies with demonstrated functionality, confirmed by NIR Western blots and > 99% purity by mass spectrometry. Backed by a top-tier industry and research network.
Baltic Sea Region Health Innovation Award: awarded at the National Health Industry Conference in Rostock.
Press & Awards
Awards for our research and selected voices from the press and academia: a look at what Ymolution is moving.
Awards · 2026Awarded at the National Health Industry Conference in Rostock. Under the patronage of Minister President Manuela Schwesig, our animal-free nano-antibody technology convinced the international jury.
Read the post
Press · 2026Ymolution as a guest at the annual reception of University Medicine Mecklenburg-Western Pomerania, in dialogue with research, clinical practice and politics.
Read the post
PressRecognition from the trade press: the renowned Laborjournal presents our animal-free approach and shows why it delivers antibodies in weeks instead of months.
Read the post
Conferences · 2025Ymolution at the 3rd Proteomics Conference in Doha: international insights, new contacts and strong interest in our nano-antibody technology ‘made in Greifswald’.
Read the post
Awards · 2025Twice recognized at the INNO Award 2025: 2nd place from the expert jury and the audience award for our animal-free nano-antibodies from the bacterial system.
Read the post
Awards · 2025Awarded at the German Biotech Days in Heidelberg. As the first company from Mecklenburg-Western Pomerania, our animal-free nano-antibody technology convinced the expert jury.
Read the postNews
1st place at the 21st National Health Industry Conference, awarded under the patronage of Minister President Manuela Schwesig.
11.06.2026Recognition from the trade press: the renowned Laborjournal presents our animal-free approach and shows why it delivers antibodies in weeks instead of months.
21.05.2026In dialogue with policymakers, academia and industry: we were guests at a top-class evening on the future of health care in Mecklenburg-Western Pomerania.
Pitch video
In just a few minutes, Managing Directors Dr. Alexander Reder and Dr. Christian Hentschker explain why the antibody revolution is not merely a vision but a necessity, and how three innovations are making it a reality.
“We make the impossible accessible.”
The team
A complementary founding team from science, business and operations, institutionally backed by University Medicine Greifswald as a shareholder.

Management
Team
Do you have a challenging antigen? Send us your high-value targets. We will identify the perfect binders.
Test Ymolution nano-antibodies in R&D or quality control.Request a quote
Co-developmentCollaboration in antibody development, in co-development projects or IVD applications.Get in touch
From 2027, fully validated production capacities will be available.From target to lead in weeks instead of months.
Contact
Tell us what you need, whether a customer inquiry or a technology partnership. We will get back to you personally and promptly.